Skip to content

Study · Observational study · 2009

5 results

Patient characteristics, drug adherence patterns, and hypoglycemia costs for patients with type 2 diabetes mellitus newly initiated on exenatide or insulin glargine.

Fabunmi R, Nielsen LL, Quimbo R, Schroeder B, Misurski D, Wintle M, Wade R

Current medical research and opinion1 Mar 2009Cited by 50 (Europe PMC)

PMID19203299 (opens in a new tab)DOI10.1185/03007990802715199 (opens in a new tab)PepBankPUB-19203299
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyOther

    In patients with type 2 diabetes with repeated pharmacy claims, exenatide was linked to a higher medication possession ratio than insulin glargine.

    In plain wordsIn patients with repeated claims, exenatide was linked to greater medicine possession than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseMedication possession ratio
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    Medication possession ratio
    68%
    exenatide
    Medication possession ratio
    58%
    insulin glargine

    Source sentences

    Summary
    For patients with two or more pharmacy claims for exenatide or insulin glargine, the 12-month medication possession ratio (MPR) was 68 +/- 29% for exenatide and 58 +/- 28% for insulin glargine (p < 0.001).
    2 context sentences
    Summary · context
    Retrospective cohort study describing patient characteristics, drug adherence patterns, and 1-year hypoglycemia rates with associated costs using an administrative claims database.
    Summary · context
    Adult subjects with type 2 diabetes had an initial claim for exenatide or insulin glargine between May 1, 2005 and June 30, 2007, and had continuous eligibility for >or= 6 months pre- and >or= 12 months post-initiation.
  2. 02HumanObservational studyOther

    In patients with type 2 diabetes, exenatide was linked to more patients meeting the adherence threshold than insulin glargine.

    In plain wordsIn patients with diabetes, exenatide was linked to more patients meeting the adherence threshold than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseMedication possession ratio at least 80%
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MPR >or= 80% was higher for exenatide (p < 0.001) and fewer patients discontinued therapy (p < 0.001).
    2 context sentences
    Summary · context
    Retrospective cohort study describing patient characteristics, drug adherence patterns, and 1-year hypoglycemia rates with associated costs using an administrative claims database.
    Summary · context
    Adult subjects with type 2 diabetes had an initial claim for exenatide or insulin glargine between May 1, 2005 and June 30, 2007, and had continuous eligibility for >or= 6 months pre- and >or= 12 months post-initiation.
  3. 03HumanObservational studyOther

    In patients with type 2 diabetes, exenatide was linked to fewer treatment discontinuations than insulin glargine.

    In plain wordsIn patients with diabetes, exenatide was linked to fewer treatment discontinuations than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTherapy discontinuation
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Treatment adherence and retention · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MPR >or= 80% was higher for exenatide (p < 0.001) and fewer patients discontinued therapy (p < 0.001).
    2 context sentences
    Summary · context
    Retrospective cohort study describing patient characteristics, drug adherence patterns, and 1-year hypoglycemia rates with associated costs using an administrative claims database.
    Summary · context
    Adult subjects with type 2 diabetes had an initial claim for exenatide or insulin glargine between May 1, 2005 and June 30, 2007, and had continuous eligibility for >or= 6 months pre- and >or= 12 months post-initiation.
  4. 04HumanObservational studySafety outcome

    In patients with type 2 diabetes, exenatide was linked to a lower probability of hypoglycemia than insulin glargine.

    In plain wordsIn patients with diabetes, exenatide was linked to a lower chance of low blood sugar than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHypoglycemic event probability
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The probability of a hypoglycemic event was significantly lower for exenatide (p < 0.005), resulting in lower associated annual costs.
    2 context sentences
    Summary · context
    Retrospective cohort study describing patient characteristics, drug adherence patterns, and 1-year hypoglycemia rates with associated costs using an administrative claims database.
    Summary · context
    Adult subjects with type 2 diabetes had an initial claim for exenatide or insulin glargine between May 1, 2005 and June 30, 2007, and had continuous eligibility for >or= 6 months pre- and >or= 12 months post-initiation.
  5. 05HumanObservational studyOther

    In patients with type 2 diabetes, exenatide was linked to lower annual hypoglycemia costs than insulin glargine.

    In plain wordsIn patients with diabetes, exenatide was linked to lower yearly costs for low blood sugar than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAnnual hypoglycemia costs
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Cost-effectiveness · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The probability of a hypoglycemic event was significantly lower for exenatide (p < 0.005), resulting in lower associated annual costs.
    2 context sentences
    Summary · context
    Retrospective cohort study describing patient characteristics, drug adherence patterns, and 1-year hypoglycemia rates with associated costs using an administrative claims database.
    Summary · context
    Adult subjects with type 2 diabetes had an initial claim for exenatide or insulin glargine between May 1, 2005 and June 30, 2007, and had continuous eligibility for >or= 6 months pre- and >or= 12 months post-initiation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.